Profit_Albash retweeted
NVIDIA ($NVDA) | Market Analysis
NVIDIA continues to deliver exceptional growth, with revenue increasing 106% year over year. Yet its stock has fallen more than 30% from its 52-week high.
Strong business performance doesn't always mean rising stock prices.
I've put together a 5-part analysis covering NVIDIA's financial performance, technical indicators, current market conditions, and long-term growth potential.
My perspective is simple: A great company can still be an expensive investment. Price matters as much as potential.
Investing with patience, backed by research.
#NVDA #NVIDIA #AI #StockMarket #Investing
Profit_Albash retweeted
$DUOL vs $TTD — Technical chart view.
$DUOL looks stronger here with improving momentum and a cleaner trend structure. Key area to hold: $115–120. A break above $130 can open the path toward $140–150.
$TTD is still in recovery mode. I’m watching $20–22 as the key confirmation zone. Until then, patience is better than aggressive adding.
Quick take: DUOL stronger, TTD needs confirmation.
Personal technical view. Not financial advice.
#DUOL #TTD #Duolingo #TheTradeDesk #Stocks #Investing #TechnicalAnalysis #StockMarket #GrowthStocks #SwingTrading
🤖 Made with AI
Profit_Albash retweeted
Is this the next Dot-Com bubble?
The S&P 500 monthly chart is still bullish, but the risk/reward is no longer easy.
Yes, the warning signs are there:
• Valuations are high
• Mega-cap concentration is extreme
• AI is driving a major growth narrative
But this is not a copy-paste of 2000.
Today’s leaders are profitable, cash-rich, and much stronger than many Dot-Com names were.
My plan: don’t panic, don’t chase. Hold quality, trim overextended winners, and keep cash ready for pullbacks.
Personal technical view. Not financial advice.
#SP500 #StockMarket #DotComBubble #AIStocks #TechnicalAnalysis #Investing #Trading #Macro #Stocks #MarketCycle
🤖 Made with AI
Profit_Albash retweeted
$PATH — UiPath could be one of the more interesting AI automation opportunities over the next 5 years.
The story is changing.
UiPath is no longer just an RPA company. It is trying to become the orchestration layer connecting:
• AI agents
• Software robots
• Employees
• Enterprise systems
At around a ~$6–7B market cap, the upside could become significant if UiPath successfully captures the agentic AI opportunity.
My 5-year scenario:
Bear Case: ~$10
Base Case: ~$25
Bull Case: ~$40–60
Exceptional Case: ~$130
A move from ~$13 to ~$130 would represent roughly a 10x return.
For that to happen, UiPath would likely need:
• ARR growth to accelerate toward 20%+
• Strong adoption of AI agent orchestration
• Continued margin expansion
• Larger enterprise contracts
• Successful competition against Microsoft, Salesforce and ServiceNow
• A major valuation re-rating
10x is not my base case.
But I believe the asymmetry is interesting enough to keep $PATH on my long-term watchlist.
The question is simple:
Can UiPath evolve from an automation company into one of the core infrastructure platforms for enterprise AI?
If yes, today’s valuation may eventually look very small.
#PATH #UiPath #AI #ArtificialIntelligence #AgenticAI #Automation #RPA #TechStocks #GrowthStocks #Stocks #StockMarket #Investing #LongTermInvesting #Multibagger #10xStocks #Software #SaaS #EnterpriseAI
🤖 Made with AI
Profit_Albash retweeted
$CRSP remains one of the most interesting high-risk biotech bets for the next 5 years.
Approved gene-editing therapy + strong pipeline in oncology, diabetes and next-gen CRISPR programs.
My 5-year view:
Base: ~$80
Bull: ~$160
Exceptional: ~$400 = ~10x
10x is not the base case, but if commercialization scales and the pipeline delivers, the upside could be significant.
#CRSP #CRISPR #Biotech #GeneEditing #GrowthStocks #10xStocks #Investing #StockMarket #LongTermInvesting
🤖 Made with AI
Replying to @LSTraderr
Based on your June average of $24.37, MRNA closed at $174.38 today after soaring ~177% on positive Phase 3 melanoma vaccine results with Merck. Your unrealized PnL is about +616%. The position has delivered exceptional returns as the long-term thesis played out. Not financial advice.
Profit_Albash retweeted
Patience + conviction = edge.
$MRNA and $TWST have both delivered strong unrealized returns from my average prices.
$MRNA: +177% — bullish recovery, holding core.
$TWST: +230% — strong breakout, holding core and trimming selectively.
My strategy is simple: protect gains, respect resistance, and let long-term winners work.
Not financial advice.
#MRNA #TWST #Biotech #Stocks #Investing #TechnicalAnalysis #StockMarket #Portfolio #LongTermInvesting
🤖 Made with AI
Profit_Albash retweeted
$TWST | Twist Bioscience
My average purchase price: $30
Current price: $87.56
5X possibility from current price: ~$437.80
I’m looking at TWST as a long-term synthetic biology platform play.
DNA synthesis, NGS tools, biotech research, drug discovery, industrial biotech, and platform expansion could create a much bigger opportunity over the coming years.
High risk. High volatility. But if synthetic biology becomes a major industry, TWST can be one of the key names to watch.
Not financial advice. Personal investment view only.
#TWST #TwistBioscience #SyntheticBiology #Biotech #BiotechStocks #Genomics #DNA #GrowthStocks #LongTermInvesting #StockMarket #Investing #ProfitAlbash
Profit_Albash retweeted
$MRNA | @moderna_tx
My average purchase price: $24
Current price: $63.96
5X possibility from current price: ~$319.80
I’m looking at Moderna as a long-term mRNA platform opportunity — not only COVID, but future vaccines, respiratory disease, oncology, personalized medicine, and next-generation biotech innovation.
High risk. High volatility. But the long-term upside could be transformational.
Not financial advice. I’m sharing my personal investment view only.
#MRNA #Moderna #Biotech #BiotechStocks #mRNA #Vaccines #HealthcareStocks #LongTermInvesting #GrowthStocks #StockMarket #Investing #ProfitAlbash
Profit_Albash retweeted
Bitcoin Cycle Watch
BTC has historically shown a cycle timing cluster of around 13–16 monthly candles after major breakout zones.
Key levels I’m watching:
Reclaim: $69.7K
Support: $61.3K / $52K
Risk: momentum still cooling
Is this cycle repeating — or is this time different?
#Bitcoin #BTC #Crypto #Investing #TradingView
Profit_Albash retweeted
My AI software shortlist for long-term investing: ServiceNow, Salesforce, and Snowflake.
The story is simple: every major company is trying to become faster, smarter, and more automated. That means enterprise software will not disappear — it will evolve.
@ServiceNow is building the workflow layer for enterprises.
@salesforce is becoming the AI-powered CRM operating system.
@Snowflake is positioning itself as the data cloud behind AI adoption.
For me, this shortlist is not about chasing hype. It is about finding companies that can benefit from AI adoption over many years, while still watching valuation, growth, profitability, and execution risk.
My mindset: build slowly, stay disciplined, and think toward 2030 — not next week.
Educational only — not financial advice.
#StockMarket #Investing #AIStocks #SoftwareStocks #ServiceNow #Salesforce #Snowflake #NOW #CRM #SNOW #LongTermInvesting #GrowthStocks #InvestorMindset #PortfolioBuilding #WealthCreation #2030Vision
🤖 Made with AI
Profit_Albash retweeted
I don’t trade for luxury.
I trade for freedom.
The goal is not to look rich.
The goal is to become financially strong enough that everyone I love feels safe, respected, and blessed.
Plan. Discipline. Patience. Risk management.
10 years from now, discipline will look like luck. 📈
#Stocks #Trading #Investing #StockMarket #FinancialFreedom #LongTermMindset #WealthBuilding #RiskManagement
$SPY $QQQ $NVDA $AAPL $TSLA $ADBE $PATH $MRNA $SMCI $TTD $DUOL $PYPL $JOBY $EVEX $AI $NIO $HUMA $CRSP $TWST $TWLO $IOT $BNTX $PRME
🤖 Made with AI
Profit_Albash retweeted
When I started investing, I thought success was about finding the perfect stock.
But slowly I learned the real game is not only stock selection — it is discipline.
The market will go up and make you feel like a genius.
The market will fall and make you question everything.
That is where mindset matters.
Long-term investors don’t win because they never see red days.
They win because they stay focused, manage risk, keep learning, and don’t allow emotions to control their decisions.
My goal is simple: build wealth patiently, invest in strong businesses, and think in years — not days.
Discipline today can become freedom tomorrow.
#StockMarket #Investing #LongTermInvesting #InvestorMindset #WealthBuilding #FinancialFreedom #GrowthStocks #PortfolioManagement #InvestmentJourney #Discipline #Patience #MoneyMindset #2030Vision
🤖 Made with AI
Profit_Albash retweeted
Gene editing is one of the most exciting — and risky — areas in biotech.
My comparison: Prime Medicine vs Beam Therapeutics.
Prime Medicine $PRME is the smaller, earlier-stage story. It uses Prime Editing, a highly flexible gene-editing approach with potential to correct a wide range of genetic mutations. The upside could be significant if early clinical programs start showing strong data, but the risk is also higher because the company is still earlier in development.
Beam Therapeutics $BEAM is the stronger and more advanced setup today. It uses Base Editing and has a deeper pipeline, stronger cash position, and clearer near-term catalysts including AATD and sickle cell programs.
My view:
$BEAM = stronger quality and better funded.
$PRME = higher asymmetric upside if execution improves.
In biotech, the biggest returns usually come before certainty — but the biggest losses also come from failed trials.
So the strategy is simple:
Study the science. Respect the risk. Size positions wisely. Think long term.
Not financial advice.
#PRME #BEAM #PrimeMedicine #BeamTherapeutics #Biotech #GeneEditing #BaseEditing #PrimeEditing #StockMarket #Investing #GrowthStocks #BiotechStocks #LongTermInvesting #InvestorMindset #RiskManagement
🤖 Made with AI
Profit_Albash retweeted
Humacyte $HUMA is one of the most interesting high-risk biotech/medtech stories on my watchlist.
The company already has an FDA-approved product, Symvess®, an off-the-shelf bioengineered human vessel for urgent vascular repair.
The big question now is execution:
Can hospital adoption grow?
Can sales scale meaningfully?
Can the hemodialysis program open a much larger market?
For me, $HUMA is not a safe core holding yet — it is a speculative, high-upside opportunity that needs patience, strong data, and careful position sizing.
Real product. Real patient need. Big potential. High risk.
Not financial advice.
#HUMA #Humacyte #Biotech #MedTech #RegenerativeMedicine #StockMarket #Investing #GrowthStocks #SpeculativeStocks #HealthcareStocks #LongTermInvesting #InvestorMindset #RiskManagement #FDA #Symvess
🤖 Made with AI
Profit_Albash retweeted
$DUOL is now sitting inside a major long-term demand zone around $110–115.
The chart is not fully bullish yet, but this is exactly where discipline matters: no panic, no FOMO, only planned accumulation.
My approach: buy gradually, respect support zones, and hold with a 2030 mindset.
Patience builds wealth.
#DUOL #Duolingo #Stocks #Investing #LongTermInvesting #StockMarket #GrowthStocks #NASDAQ #WealthBuilding #InvestorMindset
🤖 Made with AI
Profit_Albash retweeted
$MRNA is still a high-risk, high-upside biotech recovery play.
The chart is rebuilding, but the real confirmation comes only after breaking key resistance zones. My plan is simple: hold core position, add slowly near strong support, and stay patient until 2030.
No panic. No FOMO. Only discipline.
#MRNA #Moderna #Biotech #Stocks #Investing #LongTermInvesting #NASDAQ #StockMarket #GrowthStocks #InvestorMindset
🤖 Made with AI
Profit_Albash retweeted
$TEM is trading near a major weekly demand zone around $42–44.
The AI healthcare story is exciting, but the chart is not confirmed bullish yet. For me, this is not a chase zone — it is a patient DCA zone.
Plan: buy slowly, add near stronger supports, and wait for confirmation above $60–65.
Discipline first. Upside later.
#TEM #TempusAI #AIStocks #HealthcareAI #Stocks #Investing #LongTermInvesting #NASDAQ #GrowthStocks #StockMarket #InvestorMindset
🤖 Made with AI
Profit_Albash retweeted
My long-term growth portfolio is built around innovation, automation, AI, biotech, and digital infrastructure.
Top holdings:
$MRNA — 14.6%
$ADBE — 12.1%
$PATH — 11.8%
$SMCI — 6.5%
$BNTX — 6.5%
Key metrics I’m watching:
$ADBE — FY2025 revenue $23.77B, +11% YoY, operating cash flow $10.03B.
$PATH — FY2026 revenue $1.61B, +13% YoY, ARR $1.85B.
$SMCI — FY2025 sales $22.0B, up from $15.0B, net income $1.0B.
$MRNA — FY2025 revenue $1.9B, cash/investments $8.1B, high-risk pipeline recovery story.
$BNTX — FY2025 revenue €2.87B, cash + securities €17.2B, strong oncology optionality.
This is not a defensive portfolio.
It is a high-risk, high-reward portfolio that requires patience, discipline, and a multi-year mindset.
My focus: hold the thesis, manage risk, think 2030.
#Investing #Stocks #PortfolioReview #GrowthStocks #LongTermInvesting #AIStocks #Biotech #SoftwareStocks #ADBE #MRNA #PATH #SMCI #BNTX #StockMarket #InvestorMindset
🤖 Made with AI
Profit_Albash retweeted
8 micro-cap stocks under ~$100M that could become $1B moonshots:
AISP, OPTT, MAIA, VTSI, IOBT, LASE, KITT, PRZO
My top 3:
AISP = best overall setup
OPTT = strongest backlog story
MAIA = biotech moonshot
Very high risk. Not financial advice.
#Stocks #Investing #MicroCaps #SmallCaps #MoonshotStocks #AIStocks #Biotech #DefenseStocks #StockMarket #GrowthStocks
🤖 Made with AI
























